Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer
- 113 Downloads
Lung cancer is the leading cause of cancer-related deaths. The aim of this study was to design solid lipid core nanocapsules (SLCN) comprising a solid lipid core and a PEGylated polymeric corona for paclitaxel (PTX) and erlotinib (ERL) co-delivery to non-small cell lung cancer (NSCLC), and evaluate their physicochemical characteristics and in vitro activity in NCI-H23 cells.
PTX/ERL-SLCN were prepared by nanoprecipitation and sonication and physicochemically characterized by dynamic light scattering, transmission electron microscopy, differential scanning calorimetry, X-ray diffraction, and Fourier-transform infrared spectroscopy. In vitro release profiles at pH 7.4 and pH 5.0 were studied and analyzed. In vitro cytotoxicity and cellular uptake and apoptosis assays were performed in NCI-H23 cells.
PTX/ERL-SLCN exhibited appropriately-sized spherical particles with a high payload. Both PTX and ERL showed pH-dependent and sustained release in vitro profiles. PTX/ERL-SLCN demonstrated concentration- and time-dependent uptake by NCI-H23 cells and caused dose-dependent cytotoxicity in the cells, which was remarkably greater than that of not only the free individual drugs but also the free drug cocktail. Moreover, well-defined early and late apoptosis were observed with clearly visible signs of apoptotic nuclei.
PTX/ERL-SLCN could be employed as an optimal approach for combination chemotherapy of NSCLC.
Key WordsErlotinib paclitaxel solid lipid core nanocapsules non-small cell lung cancer
Acetate buffer solution
Dynamic light scattering
Dulbecco’s Modified Eagle’s medium
Differential scanning calorimetry
Epidermal growth factor receptor
Fluorescence-activated cell sorting
Fetal bovine serum
Fourier-transform infrared spectroscopy
High-performance liquid chromatography
Molecular weight cut-off
Non-small cell lung cancer
Small cell lung cancer
Solid lipid core nanocapsules
Transmission electron microscopy
Tyrosine kinase inhibitor
Acknowledgments and Disclosures
This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2015R1A2A2A01004118, 2015R1A2A2A04004806, and by the Medical Research Center Program (2015R1A5A2009124) through the NRF funded by MSIP).
Compliance with Ethical Standards
Conflict of Interest
The authors have no conflict of interest to declare.
- 3.Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5(S4):S389–96.Google Scholar
- 5.Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst. 2002;94(3):173–81.Google Scholar
- 6.Rosell R, Crino L. Pemetrexed combination therapy in the treatment of non-small cell lung cancer. Semin Oncol. 2002;29:23–9.Google Scholar
- 7.Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicenter, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521–9.Google Scholar
- 9.Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM, et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small cell lung cancer previously untreated. Ann Oncol. 2002;13(1):108–15.Google Scholar
- 13.Grunberg SM, Crowley JJ, Livingston RB, Muggia FM, MacDonald JS, Williamson SK, et al. Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A southwest oncology group study. Cancer Chemother Pharmacol. 1991;28(3):211–3.Google Scholar
- 15.Monnet I, de Cremoux H, Soulie P, Saltiel-Voisin S, Bekradda M, Saltiel JC, et al. Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol. 2002;13:103–7.Google Scholar
- 17.Sculier JP, Ghisdal L, Berghmans T, Branle F, Lafitte JJ, Vallot F, et al. The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature. Br J Cancer. 2001;84(9):1150–5.Google Scholar
- 18.Hesketh PJ, Tansan S, Caquioa PB, Hesketh A, Blanchard R, DiMartino N, et al. Treatment of advanced non-small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C. Cancer. 1993;71(3):717–20.Google Scholar
- 19.Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17(10):3188–94.Google Scholar
- 20.Babiak A, Hetzel J, Godde F, Konig HH, Pietsch M, Hetzel M, et al. Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial. Br J Cancer. 2007;96:1052–6.Google Scholar
- 22.Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23(1):190–6.Google Scholar
- 23.Chen YM, Shih JF, Lee CS, Chen MC, Lin WC, Tsai CM, et al. Study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Lung Cancer. 2003;39(2):209–14.Google Scholar
- 25.Tran TH, Thapa RK, Nguyen HT, Pham TT, Ramasamy T, Kim DS, et al. Combined phototherapy in anti-cancer treatment: therapeutics design and perspectives. J Pharm Invest. 2016;46(6):505–17.Google Scholar
- 26.Lilenbaum R, Villaflor VM, Langer C, O’Byrne K, O’Brien M, Ross HJ, et al. Single-agent versus combination chemotherapy in patients with advances non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009;4(7):869–74.Google Scholar
- 27.Santos FN, de Castria TB, Cruz MRS, Riera R. Chemotherapy for advances non-small cell lung cancer in the elderly population. (review) Cochrane Database Syst Rev. 2015; https://doi.org/10.1002/14651858.CD010463.pub2.
- 31.JL X, Jin B, Ren ZH, Lou YQ, Zhou ZR, Yang QZ, et al. Chemotherapy plus erlotinib versus chemotherapy alone for treating advanced non-small cell lung cancer: a meta-analysis. PLoS One. 2015; https://doi.org/10.1371/journal.pone.0131278.
- 38.Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523–80.Google Scholar
- 40.Gupta B, Poudel BK, Pathak S, Tak JW, Lee HH, Jeong JH, et al. Effects of formulation variables on the particle size and drug encapsulation of imatinib-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2016;17(3):652–62.Google Scholar
- 43.Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a box-Behnken design. Int J Nanomedicine. 2011;6:683–92.Google Scholar
- 44.Gupta B, Pathak S, Poudel BK, Regmi S, Ruttala HB, Gautam M, et al. Folate receptor-targeted hybrid lipid-core nanocapsules for sequential delivery of doxorubicin and tanespimycin. Colloids Surf B: Biointerfaces. 2017;155:83–92.Google Scholar
- 46.Gupta B, Poudel BK, Tran TH, Pradhan R, Cho HJ, Jeong JH, et al. Modulation of pharmacokinetic and cytotoxicity profile of imatinib base by employing optimized nanostructured lipid carriers. Pharm Res. 2015;32(9):2912–27.Google Scholar
- 47.Gupta B, Ramasamy T, Poudel BK, Pathak S, Regmi S, Choi JY, et al. Development of bioactive PEGylated nanostructured platforms for sequential delivery of doxorubicin and imatinib to overcome drug resistance in metastatic tumors. ACS Appl Mater Interfaces. 2017;9:9280–90.Google Scholar